

Department of Public Safety and Correctional Services

Office of the Secretary

300 E. JOPPA ROAD • SUITE 1000 • TOWSON, MARYLAND 21286-3020 (410) 339-5000 • FAX (410) 339-5071 • TOLL FREE (877) 379-8636 • V/TTY (800) 735-2258 • www.dpscs.maryland.gov

STATE OF MARYLAND

LARRY HOGAN GOVERNOR

BOYD K. RUTHERFORD LT. GOVERNOR

STEPHEN T. MOYER SECRETARY

WILLIAM G. STEWART DEPUTY SECRETARY ADMINISTRATION

J. MICHAEL ZEIGLER DEPUTY SECRETARY OPERATIONS

RHEA L. HARRIS ASSISTANT SECRETARY PROGRAMS AND SERVICES

DAVID N. BEZANSON ASSISTANT SECRETARY CAPITAL PROGRAMS Amendment #3
To
Request For Proposals (RFP)
Pharmacy Services
Solicitation No. Q0016025

Ladies and Gentlemen:

This Addendum is being issued to amend and clarify certain information contained in the above named RFP. All information contained herein is binding on all Offerors who respond to this RFP. Specific parts of the RFP have been amended. The following changes/additions are listed below. New language has been double underlined and marked in bold (ex. new language deleted has been marked with a strikeout (ex. language deleted).

1. AMEND § 1.2.9 as follows:

1.2.9 Clinical Liaison — The Contractor shall designate one Clinical Doctor of Pharmacy (Pharm.D.) to act as the Contractor's Clinical Liaison to the CMO and who will be the designated co-chairperson for the Department's quarterly Statewide Pharmacy & Therapeutics Committee (P&T Committee) meetings. This Contractor Clinical Liaison is in addition to the five (5) Contractor Clinical Pharm.Ds required under RFP § 3.2.17 and will have the obligation to be responsive to any requests by the DPSCS CMO to attend other meetings as required and facilitate problem solving regarding medication utilization with other vendor statewide medical and mental health Directors as requested. The Clinical Liaison will also respond to any inquiries or concerns raised by the DPSCS Chief Nursing Officer.

2. AMEND the Attachment F – Financial Proposal Form Instructions Tab as follows:

E) On the Pharmaceuticals & Supplies Tab, in Column F, provide the AAC per Unit of Measure DPSCS would pay (per tab, cap, vial, inhaler, syringe, can, bottle, kit, etc.) for each Brand and Generic Pharmaceutical or Supply as of <u>June July</u> 2017, based upon Offeror's manufacturer/wholesaler invoicing for the month of <u>June July</u> 2017. If the Offeror did not purchase a particular Pharmaceutical or Supply during the month of July 2017, the most recent invoice prior to that month should be used to establish pricing. This AAC per Unit of Measure will be multiplied by DPSCS' Annual Estimated Quantity, totaled, and the proposed Discount applied for each respective year of the Contract base term and the two-year

renewal option resulting in the Grand Total for Brand & Generic Pharmaceuticals & Supplies which will automatically populate in the Summary Tab.

- 3. AMEND the Attachment F Financial Proposal Form Instructions Tab as follows:
- L.) Include with the Financial Proposal: Provide a copy or copies of a manufacturer/wholesaler invoice(s) that documents the AAC per Unit of Measure for all (100%) of the Pharmaceuticals & Supplies included in the Pharmaceuticals Tab as of <u>June</u> July 2017. If the Offeror did not purchase a particular Pharmaceutical or Supply during the month of <u>June</u> July 2017, then provide a copy of the manufacturer/wholesaler invoice for the most recent purchase prior to <u>June</u> July 2017. Invoices shall be organized consistent with DPSCS' Pharmaceuticals List as provided on the Pharmaceuticals & Supplies Tab.
- 4. AMEND the Key Information Summary Sheet as follows:

Proposal Due (Closing)
Date and Time:

Tuesday, August 22, 2017, at 2 PM Local Time Monday, September 25, 2017, at 2 PM Local Time

Issued and authorized by

<signed>
Rachel J. Cruse
Procurement Officer